Compare GoPro Inc (GPRO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs GSK plc — how do they compare? GoPro Inc trades at $0.59 (market cap $114.41M), while GSK plc trades at $50.36 (market cap $102.60B). The key difference: GSK plc is far larger — about 896.8× GoPro Inc's market cap, and GSK plc pays a 3.57% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | GSK | |
|---|---|---|
Market Cap | $114.41M | $102.60B |
Sector | Technology | Health |
52-Week High | $2.88 | $61.18 |
52-Week Low | $0.62 | $38.22 |
Enterprise Value | $173.19M | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.57, down 18.48% in the last session, reflecting ongoing operational challenges. The company shows deteriorating fundamentals with negative net income margins (-28.52%) and consecutive earnings misses. Technical indicators signal bearish momentum, while cash flow remains negative. Recent news highlights a strategic review process for potential sale alternatives as the company faces significant financial stress.
The outlook remains highly speculative with substantial execution risks. Investment opportunity hinges entirely on successful strategic alternatives, while risks include persistent cash burn, competitive pressures, and potential dilution from recent financing. The stock presents a binary outcome scenario dependent on corporate action success.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
